The FDA approved UCB’s Cimzia (certolizumab pegol injection) for an expanded indication for moderate-to-severe plaque psoriasis.

The FDA cleared the additional indication based on phase 3 trials that found the drug significantly improved symptoms and the clinical benefit continued through 48 weeks.

The approval follows a recent update to Cimzia’s labeling for use in pregnancy and breastfeeding.